- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03131544
MRI Guided Transrectal Prostate Laser Ablation for Benign Prostatic Hypertrophy (BPH)
June 27, 2018 updated by: Prostate Laser Center, PLLC
Over 100,000 BPH procedures are performed annually in the US.
The purpose of this study is to evaluate the effectiveness of performing MRI guided transrectal laser ablation using a 980 nm laser (VisualaseTM by Medtronic, Inc., a Minnesota, U.S.A. company) to treat benign prostatic hypertrophy (BPH).
The laser system will be used to necrotize urological soft tissue within the prostate under MRI guidance.
This will be a single center, single arm prospective trial with an anticipated enrollment of 10 men.
Patients who elect this treatment option and choose to be part of the study will be enrolled consecutively.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Prostate Laser Center, PLLC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
43 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Diagnosis of lower urinary track symptoms (LUTS).
- Prostate volume of 40 - 200 cc.
- Men ≥ 45 years old.
- IPSS ≥ 15.
- BPH Impact Index ≥ 5.
Exclusion Criteria:
- History of prostate or bladder cancer, pelvic radiation, untreated bladder stones, or findings suggestive of likely underlying prostate cancer.
- Need to catheterize to relieve obstruction.
- Daily use of incontinence materials/padding.
- Neurogenic or hypotonic bladder, Parkinson's Disease, or a history of uncontrolled diabetes.
- Prior interventional or surgical treatment of BPH.
- Penile prosthesis.
- Artificial urinary sphincter or collagen bladder injection.
- Urethral stricture.
- Bleeding disorder/coagulopathy.
- Inability to refrain from blood thinners in the peri-procedural period.
- Inability or chooses not to provide informed consent.
- Any serious medical condition which would make proceeding to treatment unsafe.
- Significant contraindication to MRI or gadolinium contrast.
- Hip replacement.
- Lack of a rectum.
- Life expectancy of less than two years.
- Unable or unwilling to complete all required questionnaires and follow-up assessments.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FLA for BPH Active Treatment
|
Patients will undergo an MRI guided transrectal ablation of tissue within the periuretheral transitional zone.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
International Prostate Symptom Score (IPSS) Change
Time Frame: Time Frame: Baseline, 2 months, 4 months, 6 months and 24 months
|
Time Frame: Baseline, 2 months, 4 months, 6 months and 24 months
|
International Prostate Symptom Score Quality of Life Question Change
Time Frame: Time Frame: Baseline, 2 months, 4 months, 6 months and 24 months
|
Time Frame: Baseline, 2 months, 4 months, 6 months and 24 months
|
BPH Impact Index Change
Time Frame: Time Frame: Baseline, 2 months, 4 months, 6 months and 24 months
|
Time Frame: Baseline, 2 months, 4 months, 6 months and 24 months
|
Sexual Health Inventory of Men (SHIM) Score Change
Time Frame: Time Frame: Baseline, 2 months, 4 months, 6 months and 24 months
|
Time Frame: Baseline, 2 months, 4 months, 6 months and 24 months
|
Number and severity of adverse events
Time Frame: Continuous until completion of the study at 2 years
|
Continuous until completion of the study at 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 17, 2017
Primary Completion (Anticipated)
October 1, 2018
Study Completion (Anticipated)
May 1, 2020
Study Registration Dates
First Submitted
April 16, 2017
First Submitted That Met QC Criteria
April 24, 2017
First Posted (Actual)
April 27, 2017
Study Record Updates
Last Update Posted (Actual)
June 29, 2018
Last Update Submitted That Met QC Criteria
June 27, 2018
Last Verified
June 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Prostate Laser Center BPH 01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on BPH
-
Yonsei UniversityTerminated
-
National Taiwan University HospitalCompleted
-
Clinical Academic Center (2CA-Braga)Not yet recruiting
-
Assiut UniversityNot yet recruiting
-
Centre hospitalier de l'Université de Montréal...Completed
-
University of North Carolina, Chapel HillBTG International Inc.Completed
-
PROCEPT BioRoboticsUnknownBPHAustralia, Lebanon, United Kingdom, Germany, New Zealand
-
Boston Scientific CorporationTerminatedBPH | BPH With Urinary Obstruction | BPH With Urinary Obstruction With Other Lower Urinary Tract SymptomsUnited States, Australia
-
Mansoura UniversityRecruiting
-
Sohag UniversityNot yet recruitingBPH | Ejaculatory Dysfunction
Clinical Trials on MRI Guided Transrectal Periuretheral Transitional Zone Ablation
-
Heinrich-Heine University, DuesseldorfGerman Cancer Research CenterUnknown
-
Toronto Sunnybrook Regional Cancer CentreSunnybrook Health Sciences Centre; Women's College HospitalRecruiting
-
Saskatchewan Health Authority - Regina AreaCompleted
-
University Hospital, Strasbourg, FranceCompleted
-
The University of Texas Medical Branch, GalvestonCompletedProstate Cancer | Magnetic Resonance Imaging | Target Lesion | Fusion Biopsy | Clinically Significant Prostate Cancer | TransperinealUnited States
-
Tulane University School of MedicineTulane UniversityCompletedFibrosis | Atrial FibrillationUnited States
-
Philips HealthcareWithdrawnProstate CancerUnited States
-
Albany Medical CollegeRecruitingProstate Cancer | Infection | PSAUnited States
-
Turku University HospitalActive, not recruitingLocalized Prostate CancerFinland
-
Hospital Clinic of BarcelonaInstitut d'Investigacions Biomèdiques August Pi i Sunyer; University of BarcelonaCompletedAtrial FibrillationSpain